Academics & Research

Immunology, Inflammation, & Infectious Disease (3i) Initiative

Funding Opportunities

Internal Funding Opportunities

We will not be offering seed grants in 2019. Check back in late fall 2020/early spring 2021 for news on our next round of Team Building Grants. 


Thank you to all who applied for our 2018 Team Building Grants. We had a large number of excellent proposals, and it was difficult for the selection committee to make their decision. This year, eight teams have been selected for funding. You can find the list of recipients here. 

In 2017, we funded six grants from 3i Initiative funds, while two additional grants were funded by the Department of Pathology and the Diabetes and Metabolism Research Center. You can find a 2017 list of the awardees.


Other Funding & Award Opportunities

Funding opportunities are broken into two groups:

Foundations and Other Organizations


Federal Funding


Click the Opportunity Number or Title to be redirected to the funding opportunity announcement.

Foundations and Other Organizations Funding Opportunities:

Foundation Grant Support: U of U Health’s Office of Advancement has an office of Foundation Relations that can help faculty with strategic approaches to private foundations. Applying for research, scholarship, and program based funding from philanthropic foundations is something all faculty should consider and pursue. Foundation Relations staff can help faculty by searching for funding opportunities, identifying foundations with ongoing initiatives in particular areas of faculty interest, providing insight about the University's current and historical relationship with foundations, reviewing proposals, and facilitating ongoing foundation relationships for faculty and their units. Faculty and staff are encouraged to reach out to Lynn Marsella Wong, Director of Foundation Relations (or through your area development officer) with any questions or to discuss an opportunity prior to approaching a funder. Lynn may be reached at 801-587-1066 or lynn.wong@hsc.utah.edu.

Organization

Title

Due Date

Crohn's and Colitis Foundation

Litwin IBD Pioneers Initiative

November 5th (Annually) 

The Litwin IBD Pioneers initiative, formerly known as the Broad Medical Research Program at the Crohn’s & Colitis Foundation, supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data. View previously funded grants.

Litwin IBD Pioneers supports researchers who are exploring all possible opportunities for diagnostic and therapeutic improvements, including novel, out-of-the-box ideas, and funds innovative and pioneering ideas that have a clinically relevant focus. Additionally, the program is open to investigators from other disciplines new to the IBD field, as well as countries outside the United States.

Crohn's and Colitis Foundation

Career Development Awards

November 5th (Annually) 

Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of inflammatory bowel disease (IBD).

Crohn's and Colitis Foundation

Senior Research Awards

November 5th (Annually) 

 To provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH).

Crohn's and Colitis Foundation 

IBD Ventures  Rolling Basis 

The Crohn’s & Colitis Foundation also seeks to engage with companies and investigators who are not necessarily interested
in or eligible for the IBDV funding at this time, but who are actively seeking to discover and develop products for positive
impact in the IBD field. Such companies and investigators are encouraged to submit a Letter of Intent as an initial step in
the identification of Foundation resources that may be of interest, including future funding opportunities.

Thrasher Research Fund

E.W. "AI" Thrasher Awards

Ongoing Dates

The Thrasher Research Fund has been awarding grants for children's medical research for over 40 years. The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year.

Bay Area Lyme Foundation

Scientific Grants

Ongoing

Bay Area Lyme Foundation accepts grant proposals on a rolling basis year round. We accept applications from universities, hospitals, and independent research entities all over the United States.

Awardees are evaluated on their concepts, ideas, methods, and resourcefulness in bringing new vision into the field of Lyme disease research. Our mission is to fund research and development of novel diagnostics and treatments for Lyme disease.

Grant recipients do not need to have previous experience in Lyme disease research. Every year, we fund researchers who, while respected in their scientific areas of focus, have never previously leveraged their knowledge and abilities for research in Lyme disease.

Alzheimer's Drug Discovery Foundation

Core Requests For Proposals

Ongoing

The Alzheimer's Drug Discovery Foundation currently has four core request programs available with rolling deadlines:

  1. Program to Accelerate Clinical Trials

  2. Biomarkers Development

  3. Prevention Beyond the Pipeline

  4. Drug Discovery

Immune Tolerance Network

Clinical Trials or Assay and Biomarker Proposals

Ongoing

Clinical Trials: The Immune Tolerance Network (ITN) accepts applications for novel clinical trials from all interested scientists from academia, industry and government, in the areas of:

  • Allergy & Asthma

  • Autoimmune Diseases

  • Kidney & Liver Transplantation

Assays & Biomarkers: In addition, the ITN accepts applications for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate markers of immune tolerance and investigating the mechanisms of clinical tolerance. For example, the ITN will consider proposals that seek to better understand clinical tolerance by utilizing ITN tolerance assay resources in existing or planned clinical trials that are funded through other sources.

The ITN does NOT accept proposals for non-human or preclinical studies.

Guthy-Jackson Charitable Foundation

Neuromyelitis Optica Spectrum Disorder Grants 

Ongoing

The Guthy-Jackson Charitable Foundation (GJCF) is committed to enhancing the scientific and clinical knowledge base by supporting innovative research to accelerate solutions for NMOSD. Funding priorities are those that advance understanding of the pathophysiology and immunology of this disease in a manner that enables translation to clinical benefit and betterment of the NMOSD patient community.

The Campbell Foundation

AIDS Research Grant

Ongoing

The Campbell Foundation in Fort Lauderdale, Fla. is committed to funding novel and groundbreaking laboratory-based HIV and AIDS research

Jeffrey Modell Foundation

C.H.I.L.D.R.E.N!

Ongoing

To alleviate disease, seek cures, and ultimately improve the quality of life of children affected with Primary Immunodeficiency throughout the world. The focus of this grant program is to investigate immunological disorders, control of infectious disease, and initiatives to decrease infant mortality. Additionally, the Jeffrey Modell Foundation encourages applicants to strongly consider addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment. 

Jeffrey Modell Foundation

Specific Defect Research

Ongoing

The goal of the Specific Defect Research Program is to support research to study the mechanisms and presentation of specific defects of the immune system, leading to a better understanding of the conditions and their impact on overall health outcomes. The Jeffrey Modell Foundation database includes high numbers of various genotypes around the world. This database can provide an excellent platform for collaboration. This can evolve into sharing patient samples and setting up international collaborative studies. Working together with the Jeffrey Modell Foundation, investigators will have access to this international database and be able to contact other sites in order to coordinate studies.

Jeffrey Modell Foundation

Translational Research

Ongoing

It is estimated that as many as 10 million people, if not more, are living with Primary Immunodeficiency worldwide. Over the past decade, identification and diagnosis of Primary Immunodeficiency has greatly expanded, and knowledge of causative genes continues to rapidly grow. Simultaneously, genomics technology is becoming more readily available and cost-effective. The time is crucial to support research that will bridge basic science discoveries to the development of clinical applications that will impact overall health outcomes. Advancing the understanding of the mechanisms of Primary Immunodeficiency diseases has the ability to provide essential knowledge of immune function. Harnessing the power of understanding the immune system represents one of the single greatest disease-fighting and life-saving strategies that biomedical science has to offer and will greatly benefit those with identified Primary Immunodeficiencies, and the millions that remain undiagnosed.

 National Multiple Sclerosis Society

Multiple Opportunities

Ongoing

The National Multiple Sclerosis Society welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation.

 Abbvie

Advancing Science through Investigator-led Research

Ongoing

The research from investigator-initiated studies may expand our understanding of our products and their potential applications. Plus, it may improve patient care and spark new ideas for further disease-related research.

The AbbVie IIS Program provides an opportunity to academic and community-based physicians and researchers worldwide interested in conducting their own research to apply for research support.

Visit the IIS Submission Portal to learn more or to apply.

Merck

Investigator Studies Program (MISP)  Ongoing

The Company Investigator Studies Program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research. This program consists of committees of medical and scientific staff from different therapeutic areas who meet regularly to review our company's investigator study proposals. Support is provided based on the scientific merit of the proposal as well as whether it is in alignment with the published areas of interest. Information related to areas of interest and requirements for submission can be found by clicking on the appropriate link for your therapeutic area.

 Submission of a proposal does not imply or guarantee approval. All proposals will be reviewed based on research merit criteria. Financial and/or product support is contingent upon full execution by both parties of the research agreement.

Antibacterial Resistance Leadership Group

Early Stage Investigator Seed Grants

Ongoing

A key component of the ARLG Mentoring Core is the availability of fellow and Early Stage Investigator (ESI) Seed Grants. Each year, up to $50,000 in direct costs will be provided to up to five ESIs for research in areas related to antibacterial resistance (AR). The purpose of the ESI Seed Grant is to allow researchers to generate preliminary data leading to additional external funding. Researchers who are in the early stages of their career (five years or less) are eligible. ESI Seed Grants can be used to support initial research in any area related to AR. Importantly, these funds can be used to give ESIs access to strains contained in the ARLG Virtual Biorepository Strain Catalogue.

For additional ESI Seed Grant information, please refer to: ARLG ESI GRANT AT A GLANCE v1

Federal Funding Opportunities

Opportunity Number Agency Title Due Date

PAR-19-198 (R01) &

PAR-19-199 (R21)

National Cancer Institute (NCI)

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer

June 10, 2020

November 6, 2020

June 10, 2021

November 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses.  Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.  

PAR-20-029

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Mental Health (NIMH)

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) 

January 7, 2021;

January 7, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment.

PAR-16-254 (R01) & 

PAR-18-923 (R21)

 National Institute of Allergy and Infectious Diseases (NIAID)

Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals 

January 14th, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged.

This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines, that go beyond what have traditionally been investigated in TB.    

PAR-19-307 (R01) &

PAR-18-923 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design

January 14th, 2021

January 14th, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

PAR-18-860

National Institute of Allergy and Infectious Diseases (NIAID)

Immune Response to Arthropod Blood Feeding

October 15th, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods.  The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal.

RFA-PS-21-003

HHS / CDC - ERA  PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices  February 15, 2021 
The purpose of this notice of funding opportunity is to conduct implementation research to understand the selection, adherence, persistence, and switching patterns associated with the use of FDA approved PrEP formulations by men who have sex with men (MSM). Two oral medications have been approved by the FDA as PrEP medications for MSM. Both are recommended for daily use, and one is also recommended for 2-1-1 use before and after sex rather than daily. An injectable long-acting PrEP medication that is administered every 2 months is expected to become available in 2022.
PAR-18-830

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Cancer Institute (NCI)


National Eye Institute (NEI)

The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)

November 7th, 2020;

June 3rd, 2021;

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA.  Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease.  Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known.  The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
PAR-18-831

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Cancer Institute (NCI)


National Eye Institute (NEI)

The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)

ovember 7th, 2020;

June 3rd, 2021;

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area ofepitranscriptomics, i.e., the chemical modifications of RNA.  Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease.  Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known.  The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). 

PAR-20-054

National Institute of Allergy and Infectious Diseases (NIAID) Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

May 11, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

PAR-19-247 (R21)

PAR-19-248 (R01) 

National Institute of Allergy and Infectious Diseases (NIAID) Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination

June 10th/18th, 2020

June 10th/18th, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.
PAR-18-781 National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)

September 9, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

PAR-20-062 (R01)

PAR-20-061 (R21)

National Cancer Institute (NCI) Co-infection and Cancer Standard NIH Dates
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment
PA-18-838 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch.
PAR-18-725 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.
PAR-18-724 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Veteran's Affairs

Research Grants

A variety of mechanisms are available, please see website for details. 

 PAR-18-712

National Institute of Allergy and Infectious Diseases (NIAID) Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) Standard NIH Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.
National Institute of Allergy and Infectious Diseases (NIAID)
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)
Standard NIH Dates

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

PA-18-739 National Institute of Allergy and Infectious Diseases (NIAID) Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional) Standard NIH Dates
The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.
PA-18-784 National Heart, Lung, and Blood Institute (NHLBI) The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed) Standard NIH Dates
The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics.
PA-18-902 National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) Standard NIH Dates

The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

CDC-RFA-CK20-2003 CDC Improving Clinical and PUblic Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats  July 31, 2020 

The Centers for Disease Control and Prevention provides support for domestic and global infrastructure to prevent and control infectious diseases that threaten the public’s health. The proposed cooperative agreement would fund organizations that represent professionals at the front line of preventing and controlling the spread of emerging and re-emerging infectious disease threats such as COVID-19, including clinicians, other healthcare professionals, healthcare systems, and other organizations and institutions responsible for infectious disease prevention and control in the United States.

This NOFO is intended to establish a roster of organizations that would be pre-identified and pre-approved for rapid funding by CDC to address emerging and re-emerging public health threats. This NOFO will establish an Approved-But-Unfunded (ABU) list of grantees. This ABU list will be utilized by CDC to effectively respond to, manage, and address the identified public health threat, in partnership with national and regional organizations. Applications seeking to conduct activities outside the scope of the program activities will be deemed non-responsive and will not be considered.

Under the proposed umbrella cooperative agreement, CDC would provide funding, as available, in support of a set of strategies that target prevention and control of emerging and re-emerging infectious diseases, including COVID-19. Collaborative activities would extend from the following program strategies: 1. DISSEMINATE AND ADOPT – Support CDC in the dissemination and adoption or implementation of guidance, clinical guidelines, and best practices for the prevention and control of emerging and re-emerging infectious diseases. 2. INFORM AND ADAPT – Inform and support CDC in the development and adaptation of guidance, tools, and best practices, including tailoring existing guidance to the needs of specific patient populations , clinical specialties, and workplace industry sectors. 3. TARGET AND TRAIN – Engage frontline personnel and lead training in CDC best practices for the broader workforce supporting the prevention and control of emerging and re-emerging infectious diseases. Target guidance and tools to better reach higher risk communities and reduce disease spread in targeted workplaces. 4. INTEGRATE AND EXTEND – Develop integrated and cross-sub-specialty networks for information sharing, problem-solving, and sharing of promising practices, including the development of rapid or living learning networks. Extend networks to reach vulnerable or hard-to-reach populations. 5. EVALUATE AND IMPROVE – Evaluate the impact and effectiveness of strategies for improved infection prevention and control practices. Implement continuous improvement by assessing and monitoring performance metrics related to prevention programs and program strategy.

PA-19-049 National Heart, Lung, and Blood Institute (NHLBI) New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed) Standard NIH Dates
The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain “resilience” – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  

PA-19-042 (R01) and 

PA-19-050 (R21)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Mental Health (NIMH)

Engaging Men in HIV Testing, Prevention, and Care Standard NIH Dates

The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care.

The R01 mechanism is intended to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

 

PA-19-020 National Institute of Allergy and Infectious Diseases (NIAID) Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) Standard NIH Dates
This Funding Opportunity Announcement (FOA) invites applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo. This FOA uses the R21 grant mechanism, while the companion FOA, RFA- AI-18-042, uses the U01 mechanism. Applicants with preliminary data and/or planning longer-term studies may wish to apply using the U01 mechanism.
PA-19-068 National Institute of Allergy and Infectious Diseases (NIAID) Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases.  

PAR-19-078 (R01) &

PAR-19-079 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Molecular and Genetic Characterization of Inborn Errors of Immunity  Standard Dates

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.       

PA-19-067 &

PA-19-066

National Institute of Allergy and Infectious Diseases (NIAID) Processing and Presentation of Non-Conventional MHC Ligands (R01 & R21) Standard Dates
This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

PA-19-082 (R01)

PA-19-083 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections Standard Dates
The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis.  This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.

PA-19-080 (R01)

PA-19-081 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Advancing Development of Rapid Fungal Diagnostics Standard Dates
The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).
PA-19-077 National Institute of Allergy and Infectious Diseases (NIAID) Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation.  This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.
PA-19-096 National Institute of Allergy and Infectious Diseases (NIAID) Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection  Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.
PAS-19-097 National Institute of Allergy and Infectious Diseases (NIAID) Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).
PAS-19-105 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) Standard Dates
The Stimulating Hematology Investigation:  New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI).  Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain.  Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. 
PAR-19-155 National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) Standard Dates
This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyond clinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations, to develop infrastructure for a clinical trial, or implement a fully designed trial will not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trials-see https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new information that answers a scientific question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.

PAR-19-172(R01)

PAR-19-173(R21)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01& R21 Clinical Trial Not Allowed) Standard Dates
This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
PA-19-237 National Institute of Allergy and Infectious Diseases (NIAID) Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.

PAR-16-228 (R01)

PAR-16-229 (R21)

National Cancer Institute (NCI) Metabolic Reprogramming to Improve Immunotherapy Standard Dates
The overall goal of this funding opportunity announcement (FOA)  is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.
PA-18-724 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

PA-18-031(R01) &

PA-18-092 (R21)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants  Standard Dates
The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.

PAR-19-193 (R01) & 

PAR-19-194 (R21)

National Cancer Institute (NCI)
National Institute on Dental and Craniofacial Research ( NIDCR )
Microbial-based Cancer Therapy -Bugs as Drugs Standard Dates

The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies.  This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy.

Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.

PAR-17-438

National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
Assay development and screening for discovery of chemical probes or therapeutic agents (R01) Standard Dates

Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

PA-17-008 (R01) & 

PA-17-007 (R18)

Agency for Healthcare Research and Quality (AHRQ)

Center for Quality Improvement and Patient Safety (CQuIPS)  

Large Research Projects for Prevention of Healthcare-Associated Infections Standard Dates

 This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects  

PA-17-114

National Institute of Allergy and Infectious Diseases (NIAID) NK Cells to Induce Immunological Memory to Prevent HIV Infection  Standard Dates

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary, hypothesis-driven research on Natural Killer (NK) cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field.

PA-17-008 (R01) &

PA-17-007 (R18)

Agency for Healthcare Research and Quality (AHRQ)

Center for Quality Improvement and Patient Safety (CQuIPS)  

Large Research Projects for Prevention of Healthcare-Associated Infections Standard Dates

 This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects  

PA-19-033 &

PA-19-034

Department of Health and Human Services  Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases  July 15, 2020 (5:00PM, no late applications accepted) 

R03 Small Grant Program.  Reissue of RFA-RM-19-011. 

 

The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.

Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins.

The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.

See Section III. 3. Additional Information on Eligibility.

Merck KGaA 2020 Research Grants  Submissions will be accepted until August 31, 2020 

The research grants program is open to scientists in all career stages who are affiliated with any research-based institution, university or company. Applicants submit their application for the focus topics containing non-confidential information only. You may apply for more than one focus topic. If your application is successful, you will be invited to submit a full proposal and join a deep-dive workshop with the other finalists in 2020.  

Submissions are accepted from scientists in all countries all over the world. 

PA-18-839 NIH / HHS  Role of Gut Microbiome Regulating Reproduction and Its Impact on Fertility Status in Women Living with and without HIV  September 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch.

 

HR001120S0052 DoD - DARPA Biological Technologies Office  Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) September 17, 2020 

DARPA - Biological Technologies Office

The goal of the HEALR program is to develop new medical countermeasures against bacterial pathogens and their toxins by leveraging host degradation and deactivation pathways.

If you have difficulty accessing the full announcement electronically, please contact:

BAA Coordinator HR001120S0052@darpa.mil

HR001120S0052@darpa.mil or visit beta.SAM.gov

 

NOT-HL-20-796 NHLBI  NOSI: Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)  July 16, 2021 

This Notice of Special Interest (NOSI) invites research applications that propose short-term, exploratory bioengineering studies. The exploratory nature of the R21 mechanism is meant to foster discovery- and design-driven bioengineering research ideas that are important across the Institute and that are critical for future hypothesis-generating projects. It is noteworthy that this program emphasizes development rather than efficacy of first-generation prototypes. The NHLBI is interested in the development of highly innovative or “blue sky” ideas for diagnostics, therapeutics, surgical technologies, computational modeling tools, smart biomaterials for self-adjusting implants, and nanotechnologies, as applied to the mission areas of the Institute.

Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications proposing to conduct clinical trials are not appropriate for this NOSI. Applicants who already have first-generation prototypes, new processes of proven feasibility, or applications proposing to validate highly innovative strategies for creating new animal models are not responsive to this announcement, but should consider applying for support under the NHLBI Catalyze Program, which plans to release funding announcements in FY2019 and FY2020. Overviews of the Catalyze program initiatives can be found at: https://www.nhlbi.nih.gov/events/2018/national-heart-lung-and-blood-advisory-council-june-2018-meeting-summary.

RFA-AI-20-036 HHS / NIH   Martin Delatney Collaboratory for Pediatric HIV Cure Research December 7, 2020 

This Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV (PLWH) is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The goal of the Martin Delaney Collaboratory program is to accelerate progress towards developing strategies to achieve either eradication of HIV infection from the body or a sustained viral remission, as defined by sustained viral suppression following cessation of antiretroviral therapy. Funded projects under this FOA will be expected to expand the knowledge base on HIV latency and persistence in pediatric populations, design and evaluate innovative cure strategies, develop and evaluate assays and other modalities to accurately characterize HIV reservoirs and translate findings to the clinical settings. This funding opportunity will target perinatally infected children and adolescents up to 24 years of age with a primary focus on early treated children.

 

RFA-AI-20-035  HHS / NIH  Martin Delaney Collaboraties for HIV Cure Research  December 7, 2020 

The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV.

 

W81XWH-20-MSRP-EHDA Department of Defense / Department of Army - USAMRAA DoD Multiple Sclerosis, Exploration - Hypothesis Development Award Synopsis 1  October 1, 2020 

The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the multiple sclerosis research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.

The proposed research project should be innovative. Innovative research may examine a novel paradigm, challenge current paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance beyond ongoing research and published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of multiple sclerosis research.

W81XWH-20-NFRP-IIRA DoD / Dept. of the Army - USAMRAA  DoD Neurofibromatosis, Investigator-Initiated Research Award  July 9, 2020 
The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.
W81XWH-20-MSRP-CTA DoD / Dept. of the Army - USAMRAA  DoD Multiple Sclerosis, Clinical Trail Award  October 1, 2020 

The MSRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, interventions, health behavioral modifications and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through larger-scale Phase I and II trials to determine efficacy in relevant patient populations.

W81XWH-20-MSRP-IIRA DoD / Dept. of the Army - USAMRAA  DoD Multiple Sclerosis, Investirgator-Initiated Research Award  October 1, 2020 

The Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to multiple sclerosis research and/or patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, clinical trial results, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data.

Applications must include preliminary and/or published data that are relevant to multiple sclerosis and the proposed research project.

W81XWH-20-NFRP-SIA DoD / Dept. of the Army - USAMRAA  DoD Neurofibromatosis, Synergistitc Idea Award  July 9, 2020
The NFRP Synergistic Idea Award supports new ideas that represent synergistic approaches to neurofibromatosis research involving two or three Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurofibromatosis research. This award is designed to support both new and pre-existing partnerships, and encourages participation of PIs from other research fields.
RFA-RM-20-019 Department of Health and Human Services Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases 
The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.
CDC-RFA-DP20-2008 HHS/ CDC   Developing and Disseminating  Strategies to Build Sustainable Lupus Awareness, Knowledge, Skills, and Partnerships  June 26, 2020
Lupus is a systemic autoimmune disease. It is estimated 161,000 to 322,000 Americans have the most common type of lupus, systemic lupus erythematosus (SLE). Although anyone can get lupus, 9 out of 10 diagnoses of lupus are in women ages 15 to 44. African American and Latino women are at greater risk for lupus than white women and usually get it at a younger age and have more severe symptoms. Lupus is also more common in Hispanic, Asian, and Native American and Alaskan Native women. The causes of lupus are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Lupus is difficult to diagnose, hard to live with and challenging to treat. Lupus has a range of symptoms often confused with other conditions, making it difficult to recognize and diagnose. Its symptoms and outcomes can be severe or fatal, its onset can be sudden, its causes are unclear and there is no known cure. This NOFO addresses several persisting gaps and inequities related to lupus. Lupus can result in a range of negative outcomes including disability, social stigma, lost productivity, absence from the workforce, reduction in quality of life, organ damage or failure or early death. Undiagnosed or late diagnosis of lupus can increase the likelihood or worsen the severity of many of these outcomes. Even with a correct diagnosis, lupus is challenging to treat. Much is needed to improve the care and quality of life for people living with the disease. The public health sector can contribute a great deal to this end and help mitigate these gaps and inequities.
Opp ID: 199851

e-ASIA Joint Research Program

( e-ASIA JRP )

Research Cooperation in the Field of "Health Research Research" on the Topics of "Infectious Diseases (including AMR), Cancer, and Mental Health, with a Focus on Precision Medicine in Cancer and Infectious Diseases May 21, 2020 
The e-ASIA Joint Research Program aims to develop a vibrant and collaborative research community in Science and Technology, to promote innovation in the East Asian region, and to contribute to the region's economic development. As part of the program, the following Member Organizations of the e ASIA JRP have agreed to implement a joint call for proposals of multilateral cooperative research activities.

UK Research and Innovation 

UK-RAS Network Robotics & Autonomous Systems 

Medical Robotics for Contagious Diseases Challenge 

Submission of video entries: September 30, 2020 

NOT-ES-20-018 HHS / NIH / NIEHS NOSI: Promoting Fundamental and Applied Research in Inflammation Resolution May 31, 2024